GUJRATHI SHEILA — SEC insider filings
SEC reporting owner CIK 1575202. 20 insider filings on record with FilingPulse; latest filed 2026-10-27.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2021-10-25 to 2026-10-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 130,000 shares, $300,573 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 100,000 shares, $3,373,240 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 100,000 shares @ $33.73 ($3,373,240) in Ventyx Biosciences, Inc., filed 2023-03-31.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ventyx Biosciences, Inc. (VTYX) | Director | 11 | 1 leg · 130,000 sh · $300,573 | 1 leg · 100,000 sh · $3,373,240 | 19 |
| Janux Therapeutics, Inc. (JANX) | Director | 6 | — | — | 8 |
| Bolt Biotherapeutics, Inc. (BOLT) | Chief Strategy Officer, Director | 2 | — | — | 4 |
| Processa Pharmaceuticals, Inc. (PCSA) | Director | 1 | — | — | 2 |
Insider filings — GUJRATHI SHEILA
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-27 | 3 | Bolt Biotherapeutics, Inc. (BOLT) | Holdings only — no transactions reported | EDGAR |
| 2026-10-27 | 4 | Bolt Biotherapeutics, Inc. (BOLT) | Grant/award (A): 72,766 @ $0 · Grant/award (A): 13,055 @ $0 · Other (J): 2,763.83 (derivative) · Other (J): 495.87 (derivative) | EDGAR |
| 2026-07-30 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 70,811.88 (derivative) · Grant/award (A): 12,311.28 (derivative) | EDGAR |
| 2026-03-04 | 4 | Ventyx Biosciences, Inc. (VTYX) | Disposition to issuer (D): 130,000 · Disposition to issuer (D): 33,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Disposition to issuer (D): 662,369 (derivative) · Disposition to issuer (D): 277,941 (derivative) · +2 more | EDGAR |
| 2025-06-13 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-12-26 | 4 | Ventyx Biosciences, Inc. (VTYX) | Purchase (P): 130,000 @ $2.31 | EDGAR |
| 2024-11-07 | 4 | Janux Therapeutics, Inc. (JANX) | Other (J): 4,611 @ $0 | EDGAR |
| 2024-06-28 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 2,500 @ $0 · Grant/award (A): 8,350 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Janux Therapeutics, Inc. (JANX) | Other (J): 2,986 @ $0 | EDGAR |
| 2024-01-23 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 15,937 (derivative) @ $0 | EDGAR |
| 2023-04-26 | 4/A | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 21,825 (derivative) @ $0 | EDGAR |
| 2023-03-31 | 4 | Ventyx Biosciences, Inc. (VTYX) | Option exercise (M): 100,000 @ $6.03 · Sale (S): 100,000 @ $33.73 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 13,301 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | Ventyx Biosciences, Inc. (VTYX) | Grant/award (A): 277,941 (derivative) @ $0 | EDGAR |
| 2021-10-25 | 4 | Ventyx Biosciences, Inc. (VTYX) | Conversion (C): 32,897 @ $0 · Conversion (C): 32,897 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-10-07 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1575202 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs